ABSTRACT
@EN Seven patients with previously untreated acromegaly and invasive pituitary macroadenomas were treated with the long-acting somatostatin analog, octreotide (Sandostatin, Sandoz) for 3~6 months, before transsphenoidal pituitary adenomectomy.
Preoperatively, treatment with octreotide for 3 months reduced the pituitary tumor size by 55~60% in 2 patients, 20~39% in 3 patients and little in the remaining 2 patients. Six patients were treated for another 3 months, but the size of the
pituiary
tumor showed no further remarkable changes. Mean basal serum GH concentration fell from 251.6 (53.0~470.0) ng/ml to 80.1 (9.5~308.0)ng/ml after 3~6 months treatment with octreotide. Postoperatively, mean basal serum GH concentration fell to 52.5
(6.1~209.0) ng/ml and the GH concentration of one patient whose pituitary tumor size decreased 65% fell into the normal range. Thus, preoperative administration of octreotide induced shrinkage of GH-producing pituitary tumors in some patients and
might
have favorable effects on the remission rate in the treated patients. (J Kor Endocrinol 8:35~41, 1993).
|